The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Dialectic Therapeutics; Intuitive Surgical; Johnson & Johnson; Merck; Regeneron
Research Funding - Agenus; Alkermes; Arvinas; AstraZeneca; BerGenBio; Daiichi Sankyo; Epizyme; Gan & Lee; Genmab; GlaxoSmithKline; Harpoon Therapeutics; Hutchison MediPharma; Jounce Therapeutics; Laekna Therapeutics; Mirati Therapeutics; Mundipharma; Novartis; Odonate Therapeutics; Onconova Therapeutics; ORIC Pharmaceuticals; Pfizer; Rgenix; Shasqi Inc.; Surface Oncology; Synlogic; Takeda; Xencor
A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Navire (Inst); Silicon Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Navire (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Silicon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Jason J. Luke
Stock and Other Ownership Interests - Actym Therapeutics; Alphamab; Arch Oncology; Kanaph Therapeutics; Mavu Pharmaceutical; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - 7 Hills Pharma; Abbvie; Alphamab; Array BioPharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Checkmate Pharmaceuticals; Compugen; CStone Pharmaceuticals; Eisai; EMD Serono; Incyte; Janssen; Merck; Mersana; Nektar; Novartis; Partner Therapeutics; Reflexion Medical; Regeneron; Ribon Therapeutics; Rubius Therapeutics; Spring Bank; Synlogic; Tempest Therapeutics; Tesaro; TTC Oncology; Werewolf Therapeutics; Xencor; Xilio Therapeutics
Research Funding - Abbvie (Inst); Agios; Array BioPharma; Astellas Pharma; Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals; Corvus Pharmaceuticals (Inst); EMD Serono; Immatics; Incyte (Inst); Kadmon; Macrogenics (Inst); Merck (Inst); Moderna Therapeutics; Nektar; Spring bank; Trishula Therapeutics; Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Array BioPharma; Bristol-Myers Squibb; EMD Serono; Janssen; Merck; Mersana; Novartis; Pyxis; Reflexion Medical; Xilio Therapeutics
 
James F. Strauss
No Relationships to Disclose
 
Xin Gao
Consulting or Advisory Role - Dendreon; Exelixis
Research Funding - Aprea Therapeutics (Inst); Arvinas (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Pfizer (Inst); Takeda (Inst)
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; Bayer; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
PEI JYE VOON
No Relationships to Disclose
 
Cong Li
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Michael Shaw
Employment - Takeda
Leadership - Takeda
Stock and Other Ownership Interests - Takeda
 
Richard C. Gregory
Employment - Takeda
Leadership - Takeda
Stock and Other Ownership Interests - Takeda
 
Kristin Horn
Employment - Takeda
Stock and Other Ownership Interests - Abbvie (I); Amgen (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); Lilly (I); Merck (I); Moderna Therapeutics (I); Pfizer (I); Procter & Gamble (I); Takeda; Takeda (I); Viatris (I)
 
John Gibbs
Employment - Takeda
Stock and Other Ownership Interests - Takeda
 
Neil Lineberry
Employment - Takeda
Patents, Royalties, Other Intellectual Property - Takeda
 
Kate Stumpo
Employment - Takeda
Stock and Other Ownership Interests - AstraZeneca; AstraZeneca (I); Bristol-Myers Squibb (I); GlaxoSmithKline (I); Pfizer (I); Takeda; Teva; Viatris (I)
 
Karim Malek
Employment - Takeda
Stock and Other Ownership Interests - ImmunoGen; May have other through investment vehicles through asset management (Merrill Lynch); Takeda
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Takeda
 
Anthony J. Olszanski
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer; Sanofi
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst)
(OPTIONAL) Uncompensated Relationships - Takeda